Cosmo Pharmaceuticals N.V. (0RGI.L)
CHF 59.0
(-1.5%)
CHF 59.0
(-1.5%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 942 Thousand EUR | -46.81% |
| 2022 | 1.77 Million EUR | -98.95% |
| 2021 | 169.02 Million EUR | 2.31% |
| 2020 | 165.2 Million EUR | 1.15% |
| 2019 | 163.33 Million EUR | 3.63% |
| 2018 | 157.62 Million EUR | 4018.71% |
| 2017 | 3.82 Million EUR | -14.19% |
| 2016 | 4.46 Million EUR | -32.2% |
| 2015 | 6.57 Million EUR | -26.34% |
| 2014 | 8.93 Million EUR | -8.52% |
| 2013 | 9.76 Million EUR | -11.58% |
| 2012 | 11.04 Million EUR | 759.81% |
| 2011 | 1.28 Million EUR | -40.99% |
| 2010 | 2.17 Million EUR | 32.52% |
| 2009 | 1.64 Million EUR | -43.44% |
| 2008 | 2.9 Million EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 4.78 Million EUR | -65.58% |
| 2005 | 13.89 Million EUR | -8.9% |
| 2004 | 15.25 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 714 Thousand EUR | 0.0% |
| 2024 Q2 | 714 Thousand EUR | 0.0% |
| 2023 Q4 | 942 Thousand EUR | 0.0% |
| 2023 Q1 | 1.39 Million EUR | -21.4% |
| 2023 Q2 | 1.39 Million EUR | 0.0% |
| 2023 FY | 942 Thousand EUR | -46.81% |
| 2023 Q3 | 942 Thousand EUR | -32.33% |
| 2022 FY | 1.77 Million EUR | -98.95% |
| 2022 Q4 | 1.77 Million EUR | 0.0% |
| 2022 Q2 | 170.91 Million EUR | 0.0% |
| 2022 Q1 | 170.91 Million EUR | 1.11% |
| 2022 Q3 | 1.77 Million EUR | -98.96% |
| 2021 Q2 | 166.91 Million EUR | 0.0% |
| 2021 FY | 169.02 Million EUR | 2.31% |
| 2021 Q3 | 169.02 Million EUR | 1.27% |
| 2021 Q1 | 166.91 Million EUR | 1.03% |
| 2021 Q4 | 169.02 Million EUR | 0.0% |
| 2020 Q4 | 165.2 Million EUR | 0.0% |
| 2020 Q2 | 163.78 Million EUR | 0.0% |
| 2020 FY | 165.2 Million EUR | 1.15% |
| 2020 Q1 | 163.78 Million EUR | 0.28% |
| 2020 Q3 | 165.2 Million EUR | 0.87% |
| 2019 Q3 | 163.33 Million EUR | 0.75% |
| 2019 Q1 | 162.12 Million EUR | 2.85% |
| 2019 Q2 | 162.12 Million EUR | 0.0% |
| 2019 FY | 163.33 Million EUR | 3.63% |
| 2019 Q4 | 163.33 Million EUR | 0.0% |
| 2018 Q1 | 3.63 Million EUR | -5.15% |
| 2018 FY | 157.62 Million EUR | 4018.71% |
| 2018 Q4 | 157.62 Million EUR | 0.0% |
| 2018 Q3 | 157.62 Million EUR | 4242.23% |
| 2018 Q2 | 3.63 Million EUR | 0.0% |
| 2017 Q4 | 3.82 Million EUR | 0.0% |
| 2017 FY | 3.82 Million EUR | -14.19% |
| 2017 Q1 | 4.25 Million EUR | -4.69% |
| 2017 Q2 | 4.25 Million EUR | 0.0% |
| 2017 Q3 | 3.82 Million EUR | -9.97% |
| 2016 Q2 | 5.83 Million EUR | 0.0% |
| 2016 FY | 4.46 Million EUR | -32.2% |
| 2016 Q1 | 5.83 Million EUR | -11.36% |
| 2016 Q3 | 4.46 Million EUR | -23.51% |
| 2016 Q4 | 4.46 Million EUR | 0.0% |
| 2015 Q4 | 6.57 Million EUR | 0.0% |
| 2015 Q3 | 6.57 Million EUR | -17.66% |
| 2015 FY | 6.57 Million EUR | -26.34% |
| 2015 Q2 | 7.98 Million EUR | 0.0% |
| 2015 Q1 | 7.98 Million EUR | -10.54% |
| 2014 Q4 | 8.93 Million EUR | 0.0% |
| 2014 Q2 | 8.79 Million EUR | 0.0% |
| 2014 Q1 | 8.79 Million EUR | -9.91% |
| 2014 FY | 8.93 Million EUR | -8.52% |
| 2014 Q3 | 8.93 Million EUR | 1.53% |
| 2013 Q1 | 10.92 Million EUR | -1.05% |
| 2013 FY | 9.76 Million EUR | -11.58% |
| 2013 Q4 | 9.76 Million EUR | 0.0% |
| 2013 Q3 | 9.76 Million EUR | -10.64% |
| 2013 Q2 | 10.92 Million EUR | 0.0% |
| 2012 Q4 | 11.04 Million EUR | 356.95% |
| 2012 FY | 11.04 Million EUR | 759.81% |
| 2012 Q2 | 876 Thousand EUR | 0.0% |
| 2012 Q3 | 2.41 Million EUR | 175.8% |
| 2011 Q2 | 1.77 Million EUR | 0.0% |
| 2011 Q4 | 1.28 Million EUR | 0.0% |
| 2011 FY | 1.28 Million EUR | -40.99% |
| 2010 Q2 | 2.56 Million EUR | 0.0% |
| 2010 Q4 | 2.17 Million EUR | 0.0% |
| 2010 FY | 2.17 Million EUR | 32.52% |
| 2009 Q4 | 1.64 Million EUR | 0.0% |
| 2009 FY | 1.64 Million EUR | -43.44% |
| 2008 FY | 2.9 Million EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 4.78 Million EUR | -65.58% |
| 2005 FY | 13.89 Million EUR | -8.9% |
| 2004 FY | 15.25 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 9000.00 CHF | -10366.667% |
| Tecan Group AG | 303.85 Million CHF | 99.69% |
| Santhera Pharmaceuticals Holding AG | 1.47 Million CHF | 36.265% |
| Basilea Pharmaceutica AG | 95.45 Million CHF | 99.013% |
| Bachem Holding AG | 218 Thousand CHF | -332.11% |
| Siegfried Holding AG | 525 Million CHF | 99.821% |
| Molecular Partners AG | 2.44 Million CHF | 61.457% |